Notice of Proposed Sale · 144
Vaxcyte, Inc.
PCVXNASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- Vaxcyte, Inc.
- Issuer CIK
- 0001649094
- SEC file number
- 001-39323
- Phone
- 650-837-0111
- Person for whose account securities are to be sold
- PICKERING GRANT
- Relationships to issuer
- Officer · Director
- Street
- 825 INDUSTRIAL ROAD, STE. 300
- City
- SAN CARLOS
- State / country code
- CA
- Postal code
- 94070
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common | 18,198 | 996,704.46 | 144,397,682 | 07/27/2026 | NASDAQ | UBS Financial Services, Inc. |
Broker / market maker — proposed row 1, entry 1
- Name
- UBS Financial Services, Inc.
- Street
- 11 Madison Ave
- Street (continued)
- 4th Floor
- City
- New York
- State / country code
- NY
- Postal code
- 10010
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common | 07/27/2026 | Exercise of Stock Options | Issuer | 16,198 | N | 07/27/2026 | NA |
| Common | 12/09/2013 | Founder Shares | Issuer | 2,000 | N | 12/09/2013 | NA |
Sales reported in the preceding three months
| Seller | Security | Sale date | Amount sold | Gross proceeds |
|---|---|---|---|---|
| Grant Pickering | Common | 06/18/2026 | 22,461 | 1,179,204.75 |
| The Claire Pickering 2020 Delaware Trust | Common | 06/18/2026 | 1,000 | 52,500.00 |
| The Benjamin Pickering 2020 Delaware Trust | Common | 06/18/2026 | 1,000 | 52,500.00 |
| Grant Pickering | Common | 06/26/2026 | 22,237 | 1,227,807.06 |
| The Claire Pickering 2020 Delaware Trust | Common | 06/26/2026 | 1,000 | 55,259.30 |
| The Benjamin Pickering 2020 Delaware Trust | Common | 06/26/2026 | 1,000 | 55,206.20 |
Seller — prior-sale row 1, entry 1
- Name
- Grant Pickering
- Street
- 825 INDUSTRIAL ROAD, STE. 300
- City
- SAN CARLOS
- State / country code
- CA
- Postal code
- 94070
Seller — prior-sale row 2, entry 1
- Name
- The Claire Pickering 2020 Delaware Trust
- Street
- 825 INDUSTRIAL ROAD, STE. 300
- City
- SAN CARLOS
- State / country code
- CA
- Postal code
- 94070
Seller — prior-sale row 3, entry 1
- Name
- The Benjamin Pickering 2020 Delaware Trust
- Street
- 825 INDUSTRIAL ROAD, STE. 300
- City
- SAN CARLOS
- State / country code
- CA
- Postal code
- 94070
Seller — prior-sale row 4, entry 1
- Name
- Grant Pickering
- Street
- 825 INDUSTRIAL ROAD, STE. 300
- City
- SAN CARLOS
- State / country code
- CA
- Postal code
- 94070
Seller — prior-sale row 5, entry 1
- Name
- The Claire Pickering 2020 Delaware Trust
- Street
- 825 INDUSTRIAL ROAD, STE. 300
- City
- SAN CARLOS
- State / country code
- CA
- Postal code
- 94070
Seller — prior-sale row 6, entry 1
- Name
- The Benjamin Pickering 2020 Delaware Trust
- Street
- 825 INDUSTRIAL ROAD, STE. 300
- City
- SAN CARLOS
- State / country code
- CA
- Postal code
- 94070
Prior-sale reporting
- Nothing to report for the preceding three months
- N
Remarks
16,198 shares represented in this filing are being sold under Grant Pickering, 1,000 shares are being sold under the Claire Pickering 2020 Delaware Trust and 1,000 shares are being sold under the Benjamin Pickering 2020Delaware Trust.
Notice signature
- Notice date
- 07/27/2026
- Signed
- /s/ UBS Financial Services Inc, as attorney-in-fact for Grant Pickering
- Plan adoption dates
- 03/03/2026
Company context
Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. VAX-31, a 31-valent PCV candidate being evaluated in the OPUS Phase 3 adult clinical program and in a Phase 2 infant clinical program, is being developed for the prevention of IPD and is the broadest-spectrum PCV candidate in the clinic today. VAX-24, a 24-valent PCV candidate, has generated positive Phase 2 clinical results in both adults and infants and is designed to cover more serotypes than any PCV on-market. VAX-31 and VAX-24 are designed to improve upon standard-of-care PCVs by covering the serotypes in circulation that cause a significant portion of IPD and are associated with high case-fatality rates, antibiotic resistance and meningitis, while maintaining coverage of previously circulating strains. VAX-XL, in earlier-stage development, also leverages the Company’s carrier-sparing, site-specific conjugation technology with the aim of further expanding coverage to deliver the broadest-spectrum candidate in the Company’s PCV franchise.